Noninvasive Brain Stimulation Training (TrainingNIBS)

October 27, 2022 updated by: Mario Stampanoni Bassi, Neuromed IRCCS

Noninvasive Brain Stimulation Training to Help Recover Brain-related Symptoms

Non-invasive cerebral stimulation techniques have shown potential in the treatment of neurological disorders such as chronic pain, Parkinson's disease, neglect, aphasia, memory, engine deficit and epilepsy In general, non-invasive cerebral stimulation techniques have been shown to be able to induce changes in cortical plasticity that may last even beyond the end of the stimulation period. Considering this potential, there is growing interest in the application of these therapeutic techniques.

Hypotheses Based on these assumptions, the underlying hypothesis behind this project is that the therapeutic use of cranial - electrical or magnetic stimulation - can aid the recovery of various brain injury symptoms.

Specific objectives This study aims to provide preliminary data about the benefits of using cortical stimulation to recover various brain injury symptoms. This will be made possible thanks to the specific skills of a multidisciplinary team of neurologists and physiatrists, healthcare professionals such as physiotherapists, occupational therapists, psychologists, speech therapists and the support of a biomedical engineer. These professional figures are already available at the UCK Neurosurgery of the IRCCS Neuromed directed by the proposer and actively collaborate to optimize the therapeutic exercise of patients with neurological damage.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Introduction TMS is a non-invasive neuronal stimulation of surface areas of the brain that since its introduction in 1985 has been frequently used in neurology as a diagnostic and research tool. TMS uses magnetic fields to induce electrical currents that cross the nervous tissue depolarizing neurons, and reproduced motions generated are recorded as electromyograph potentials. TMS is able to explore the functionality of the cortical-spinal system, measure cortical excitability, mapcortical features, and evaluate brain modulators.

Repetitive transcranial magnetic stimulation (rTMS) is frequently used in the experimental field for cortical function scans and modulation of the intrinsic cortical plasticity. In particular, high frequency rTMS has facilitating effects on cortico-spinal excitability and the low-frequency one is usually inhibitory. rTMS is a method of extreme interest for the possible therapeutic role in conditions of altered cerebral excitability, both psychiatric (schizophrenia, posttraumatic stress disorder, obsessive-compulsive disorder, major depression) and neurological (epilepsy , stroke, degenerative diseases). At experimental level, the actual stimulation is compared with an inactive stimulus called sham, which acts as a control condition.

Direct Transcranial Electric Stimulation (tDCS) requires the application of weak electrical currents directly to the head for several minutes. These currents generate an electric field modulating neural activity based on the application mode. tDCS alters the rate of discharge of neurons. In fact, cathodic polarization applied to the motor cortex can induce a robust reduction in cortical excitability, while anodic polarization increases the excitability of the motor cortex. The short-term effects of tDCS are probably due to a change in neural membrane polarization. Similarly to rTMS, these changes last even after the end of stimulation for periods ranging from minutes to hours. Thus, tDCS can modify performance in many cognitive tasks.

Non-invasive cerebral stimulation have demonstrated a potential for the treatment of neurological disorders such as chronic pain, Parkinson's disease, neglect, aphasia, memory, motor deficiency and epilepsy. In general, non-invasive brain stimulation techniques have shown to induce changes in cortical plasticity that may last even beyond the end of the stimulation period. Considering this potential, there is an increasing interest in the application of these techniques in the therapeutic field.

In our study, we suggest evaluating any variations in the muscular tone of the lower limbs as a result of high frequency repetitive transcranial magnetic stimulation (rTMS) in patients with multiple sclerosis with relapsing-remitting pattern without evidence of medullary demyelination areas. rTMS allows modulation of intracortical excitability and can therefore modify the control of spinal excitability.

Sensory disorders are frequently observed within neurological disorders and are a possible cause of disability. Recent studies based on non-invasive stimulation techniques have shown interesting results in modulation of tactile sensory functions in healthy subjects. tDCS is capable of inducing a plastic change in motor and somatosensory areas. Several studies have reported anodic tDCS stimulation that can reduce both chronic and acute pain in different conditions. In addition, anodic tDCS stimulation can improve the loss of tactile sensitivity resulting from Multiple Sclerosis.

Most patients with Parkinson's Disease develop after several years of treatment with a number of clinical complications, including dyskinesias, involuntary pathological, sometimes frankly, dystonic movements. Pathological Long Term Potentiation (LTP) phenomena were observed in the stigma of parkinsonian rats that developed dyskinesias following L-dopa treatment. Low-frequency electric stimulation of single cells induces a reversal of enhanced synaptic responses, a phenomenon known as depotentiation.

Several authors have observed that in patients with focal dystonia there is a lack of intracortical inhibition of controls. A pilot study examined the effects of slow rTMS on the motor cortex, highlighting normalization of intracortical inhibition and improving clinical symptoms.

The role of TMS in the treatment of major drug-resistant depression has been amply defined. Some early studies demonstrated that a high-frequency focal pacing of the left-sided prefrontal cortex (DLPFC) induced symptom improvement, quantifiable as a reduction in the score to the Hamilton Depression Rating Scale, probably via an increase in the content of brain monoamines. Studies on cerebral blood flow have also shown an increase in activity in the stimulated DLPFC.

It is now accepted that rTMS has the same efficacy, in the most potent drug-resistant depression, of electroconvulsive therapy, with virtually null side effects.

Hypothesis Based on these assumptions, the underlying hypothesis behind this project is that the therapeutic use of cranial - electrical or magnetic stimulation - can aid the recovery of various brain injury symptoms.

Specific objectives This study aims to provide preliminary data about the benefits of using cortical stimulation to recover various brain injury symptoms. This will be made possible thanks to the specific skills of a multidisciplinary team of neurologists and physiatrists, healthcare professionals such as physiotherapists, occupational therapists, psychologists, speech therapists and the support of a biomedical engineer. These professional figures are already available at the UCK Neurosurgery of the IRCCS Neuromed directed by the proposer and actively collaborate to optimize the therapeutic exercise of patients with neurological damage.

Population of the study The sample estimate was made by analogy after a literature analysis. Considering the risk of abandonment quite high, our intention is to recruit at least 100 subjects in a population of patients with cerebral injury who are involved in the neurological department of IRCCS. Neuromed in Pozzilli, featuring the symptoms described below in the inclusion criteria Inclusion and exclusion criteria are specified below.

Experimental design Double-blind prospective study, between randomized, placebo-controlled parallel groups.

Patients will undergo a cerebral pacing program listed below and differentiated according to the type of symptom presented. All conventional therapies taken by patients will be recorded by the operators. Patients will be divided into Stimulation and Sham (control) groups and will be evaluated at zero time before starting treatment (T-0W) after 6 weeks to evaluate the effects at the end of treatment (T-6W) and at 12 weeks (T-12W) to evaluate the maintenance of long-term effects. Randomization will be balanced in accordance with age, sex and schooling.

The physiotherapy or speech therapy approach will be different between patients considering the different types of brain damage and the different levels of disability, according to the rehabilitation unit team for each case.

Spasticity Patients will be evaluated clinically, using a clinical scale to quantify muscle tone in the various districts (Ashworth scale) and neurophysiologically by eliciting the H reflection. The electrophysiological parameters detected will be: M response, H reflex and its M / H ratio. Patients with spasticity to lower limbs will be enrolled in continuous interferon therapy and free of cortisone for at least 30 days.

The runtime rTMS will be applied to the motor at rest (RMT) on the primary motor area for the lower limb, 5 Hz (excitatory) with 20 trains of 10 sec (50 train stimuli, 1000 total stimuli) with intertree intervals of 30 seconds (total 22 min. Ca) on the primary motor cortex for the lower limb and we will measure the H reflex before and after the stimulation session. The treatment will last 2 weeks with daily sessions.

Dyskinesia Patients with clinically diagnosed discontinuous L-Dopa treatment history will be enrolled.

They will be given rTMS for 7 consecutive days with the following stimulation parameters: 1 Hz frequency; 90% Active Motor Threshold intensity; Train duration 899 sec (900 stimuli). At the end of each individual stimulation session patients will be subjected to neurological evaluation of the symptoms.

Sensory Deficits Patients with reduced tactile sensitivity to upper or lower limbs will be enrolled. Patients with peripheral neuropathy, psychiatric disorders, cognitive deficits, epilepsy will be excluded. TDCS stimulation will be administered for 5 consecutive days at 2 mA for 20 minutes. The anode will be placed 2 cm behind the C3 / C4 points of the defective hemisphere. The reference electrode will be positioned over the contralateral control region. Sham stimulation will have the same parameters. Clinical evaluation will be performed before and after treatment, and at a distance of 1, 2 and 4 weeks.

Pain Patients with neuropathic pain in the upper or lower limbs, VAS score of at least 40, will be enrolled in the absence of analgesic treatment for at least one month. Subjects with peripheral neuropathic pain, headache, psychiatric disorders, cognitive deficits, epilepsy will be excluded. TDCS stimulation will be administered as above. The anode will be positioned 2 cm behind the CP's defective hemisphere points. The reference electrode will be positioned over the contralateral control region. Clinical evaluation will be performed before and after treatment, and at a distance of 1, 2 and 4 weeks.

Aphasia Patients with flu-like and non-fluent language disorders will be enrolled, evaluated by clinical scales and clinical visits. TDCS stimulation will be administered for 5 consecutive days, followed by 2 days of pause and subsequent 5 days of 1 mA stimulation for 20 minutes. The anode will be located at the Broca or Wernicke area level. The cathode will be placed on the homologous counterpartical area of the anode. Logopedic therapy will be coupled to true tDCS stimulation and sham. Clinical evaluation will be performed before and after treatment, and at a distance of 1, 2 and 4 weeks.

Dysphagia Patients with swallowing disorders will be enrolled, evaluated by clinical scales, logopedic visit, Otorhinolaryngology visit. TDCS stimulation will be administered for 5 consecutive days at 2 mA for 20 minutes. The anode will be positioned at the level of the dominant motor cortex to control the muscles of the swallowing. The reference electrode will be positioned over the contralateral control region. Logopedic therapy will be coupled to true tDCS stimulation and sham. Clinical evaluation will be performed before and after treatment, and at a distance of 1, 2 and 4 weeks by logopedic, neurophysiological and ORL assessment.

Major Depression In the study, 15 patients with major DSM-IV depression diagnosed with proven drug resistance will be enrolled. Of these, five will be submitted to rTMS of the left dorsolateral prefrontal cortex (DLPFC), five at rTMS of the right DLPFC and five at sham stimulation. The study will be conducted in single blind. The rTMS session will last (15) consecutive days. The stimulation parameters will be: 10 Hz frequency; 100% RMT intensity; Train duration 10 sec (100 stimuli); Inter-train interval 1 minute; n. Total of the terrors 12; Duration of a session about 13 minutes. Hamilton Depression Rating Scale will be administered on the first day before stimulation, and on the last day after stimulation.

Expected results The present study aims to provide preliminary data on the benefits of cortical stimulation for the recovery of various brain injury symptoms.

The expected result is that neurostimulation training potentiates the recovery of the various symptoms considered in the present study, resulting in brain damage.

Study Type

Interventional

Enrollment (Anticipated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
    • Isernia
      • Pozzilli, Isernia, Italy, 86077
        • Recruiting
        • IRCCS Neuromed

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

The sample estimate was made by analogy after a literature analysis. Considering the risk of abandonment quite high, our intention is to recruit at least 100 subjects in a population of patients with cerebral injury who are involved in the neurological department of I.R.R.C.S. Neuromed by Pozzilli, featuring the symptoms described below in the inclusion criteria

Inclusion criteria:

  • Males or females aged between 18 and 80;
  • Presence of: Disinfection, Multiple Sclerosis, Depression, Sensory Disorder or Neuropathic Pain;
  • Female subjects can not be pregnant, can not breastfeed, have been born at least three months before the beginning of the study, undertake not to schedule a pregnancy for the duration of the study;
  • Patients should be able to follow protocol guidelines throughout the study;
  • Patients should be able to understand the aims and risks of the study;
  • Signature of informed consent, approved by our Ethics Committee.

Exclusion criteria:

  • Tumors or systemic infections;
  • Patients with impaired hepatic function (ALT> 3 x Upper Limit Normal (ULN), Alkaline Phosphatase> 2 x ULN, bilirubin tot> 2 x ULN if associated with any increase in ALT or alkaline phosphatase); Severe or moderate renal failure;
  • Patients with TMS or tDCS (pacemaker, intracerebral metal clip, epilepsy ...)
  • Patients with other pathologies which, according to the scientific officer's opinion, prevent recruitment;
  • Patients unable to even partially understand and want.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: real stimulation
Cranial - electrical or magnetic stimulation. Stimulation will be different according to clinical conditions, as specified elsewhere.
Device: non invasive brain stimulation

TDCS stimulation will be administered for 5 consecutive days at 2 mA for 20 minutes.

TMS stimulation parameters will be: 10 Hz frequency; 100% RMT intensity; Train duration 10 sec (100 stimuli); Inter-train interval 1 minute; n. Total of the terrors 12; Duration of a session about 13 minutes.
Placebo Comparator: sham stimulation
Patients will be treated as in the "Real stimulation" arm, but no electrical or magnetic stimulation will be induced.
Device: sham stimulation
Placebo treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
FIM
Time Frame: up to 3 years
Functional Independence Measurement (FIM) (Chumney et al., 2010)
up to 3 years
stroke
Time Frame: up to 3 years
NIH Stroke Scale / Score (NIHSS)
up to 3 years
disability
Time Frame: up to 3 years
Expanded Disability Status Scale (EDSS) (Kurtzke, 1983)
up to 3 years
parkinson
Time Frame: up to 3 years
Unified Parkinson's Disease Rating Scale (Rammer et al. )
up to 3 years
depression
Time Frame: up to 3 years
Beck Depression Inventory (BDI) (Beck, 1972)
up to 3 years
Barthel's Activities of Daily Living (ADL) (O'Sullivan et al 2007)
Time Frame: up to 3 years
Abilities of daily living
up to 3 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
neuronal plasticity
Time Frame: up to 3 years
Transcranial Magnetic Stimulation (TMS) will be used to evaluate the change of neuronal plasticity in a subgroup of patients who will not present contraindications to the method. The TMS uses short-lived magnetic fields and high intensity applied at the scalp level to activate the neurons of a small region of the cerebral cortex through an electromagnetic induction. When these impulses are applied repeatedly, it is possible to induce plastic modification of cortical excitability. If these changes are induced at the level of the motor cortex, they can be measured by recording a motor evoked potential (MEP) at the muscle level represented at the stimulated region level. Any increase or decrease in AMP amplitude, which persists after the end of TMS repetitive stimulation, indicates that there have been changes in the cortical, LTP or depression (LTD).
up to 3 years
posture
Time Frame: up to 3 years
Stabilometric Platform
up to 3 years
locomotion
Time Frame: up to 3 years
Gait Analysis
up to 3 years
deglutition
Time Frame: up to 3 years
Electrophysiological and Fiberendoscopic Deglutition Study
up to 3 years
Cognition
Time Frame: up to 3 years
ad-hoc task
up to 3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Neuromed IRCCS

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 22, 2017

Primary Completion (Anticipated)

December 31, 2024

Study Completion (Anticipated)

December 31, 2025

Study Registration Dates

First Submitted

July 13, 2017

First Submitted That Met QC Criteria

July 20, 2017

First Posted (Actual)

July 25, 2017

Study Record Updates

Last Update Posted (Actual)

October 31, 2022

Last Update Submitted That Met QC Criteria

October 27, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRCCS_Neuromed

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Brain Injuries

Clinical Trials on non invasive brain stimulation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe